Drug Development | Novartis

Story
Sep 08, 2023
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Story
Nov 01, 2022
A scientist from the start – Q&A with NIBR President Fiona Marshall
Story
Jun 23, 2022
Renewing our commitment to neglected tropical disease and malaria elimination
Featured News
May 23, 2022
Novartis at ASCO and EHA 2022
Media Release
Jan 10, 2022
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Media Release
Dec 20, 2021
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Media Release
Dec 02, 2021
Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
Story
Nov 18, 2021
The art of drug design in a technological age
Story
Nov 04, 2021
To make a difference, start with patients
Media Release
Sep 23, 2020
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Media Release
Oct 09, 2020
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
Media Release
Jan 26, 2021
En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments